Jane Street
INSY

Jane Street’s Insys Therapeutics, Inc. INSY Stock Holding History

Jane Street’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-14,200
Closed -$137K – 5745
2017
Q4 		$137K Buy
+14,200
New +$92.9K ﹤0.01% 4300
2015
Q3 		– Sell
-10,800
Closed -$388K – 4402
2015
Q2 		$388K Buy
+10,800
New +$336K ﹤0.01% 2545

Other funds holding INSY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Jane Street's INSY Position: Q4 2018 in Review

Jane Street sold out of Insys Therapeutics, Inc. (INSY) in Q4 2018, closing a stake of 11,161 shares — an estimated $113K sold.

Jane Street first reported a position in INSY in Q4 2013 and held it in 10 quarters. The position peaked at $1.21M in Q3 2015. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2018.

  • Jane Street reported no remaining Insys Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Jane Street sold 11,161 Insys Therapeutics, Inc. shares in Q4 2018, an estimated $113K.
  • Jane Street first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 10 quarters.
  • Jane Street's Insys Therapeutics, Inc. position peaked at $1.21M in Q3 2015.
  • 113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2018.

Based on Jane Street's 13F filing for Q4 2018, filed 15 Feb 2019.